Analyst Price Target is $27.80
▲ +26.71% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Tyra Biosciences in the last 3 months. The average price target is $27.80, with a high forecast of $33.00 and a low forecast of $15.00. The average price target represents a 26.71% upside from the last price of $21.94.
Current Consensus is
Moderate Buy
The current consensus among 5 polled investment analysts is to moderate buy stock in Tyra Biosciences. This rating has held steady since November 2023, when it changed from a Buy consensus rating.
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.
Read More